Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.60 |
| ▸ | DRD2 | P14416 | 6/20 | 0.54 |
| ▸ | DRD4 | P21917 | 6/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23482004 | 0.84 | DRD3 (0.48) | HRH3DRD2DRD4DRD3MEN1 | |
| SCHEMBL10508496 | 0.77 | HRH3 (0.97) | HRH3DRD2DRD3CHRNA7 | |
| SCHEMBL23481977 | 0.77 | HRH3 (0.62) | HRH3CHRNA7 | |
| SCHEMBL31061131 | 0.76 | HRH3 (1.00) | HRH3DRD2DRD3CHRNA7 | |
| SCHEMBL23458882 | 0.76 | DRD2 (0.49) | DRD2DRD4DRD3MEN1 | |
| SCHEMBL29919242 | 0.76 | DRD2 (0.49) | DRD2DRD4DRD3MEN1 | |
| SCHEMBL3846224 | 0.73 | PARP1 (0.46) | HRH3DRD2DRD4DRD3KCNJ1 | |
| SCHEMBL187916 | 0.72 | HRH3 (0.67) | HRH3DRD2MEN1CHRNA7 | |
| SCHEMBL7503276 | 0.72 | DRD2 (0.51) | DRD2DRD4DRD3 | |
| SCHEMBL7442607 | 0.72 | DRD2 (0.51) | DRD2DRD4DRD3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2021111124-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | HRH3 4235/4885DRD2 4008/4885DRD4 3499/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | HRH3 4235/4885DRD2 4008/4885DRD4 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.